Category
blog
-
2023
-
US FDA grants EUA to InflaRx’s Covid-19 treatment
-
Caribou’s CAR-T cell therapy receives fast track status
-
Merck and Proxygen partner in deal worth
-
Sartorius signs agreement to acquire Polyplus
-
Johnson & Johnson offers $8.9bn to resolve all talcum powder lawsuits
-
Signs of change in Korean diabetes treatment market
-
FDA Classifies Abbott’s Freestyle Libre Readers Recall as the Most Serious Type
-
India emerging as world’s leading pharmacy hub
-
Merck, Eisai decide to discontinue advanced melanoma therapy trial
-
US FDA advisers to weigh full approval for Eisai-Biogen’s Alzheimer’s drug